Vanda Pharmaceuticals Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Mihael H. Polymeropoulos
- Full Time Employees
- 533
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2200 Pennsylvania Avenue NW Washington DC United States of America 20037
- IPO Date
- Apr 12, 2006
- CIK
- 0001347178
- Website
- vandapharma.com
- Similar Companies
- Business
- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) develops and commercializes innovative biopharmaceutical therapies focused on addressing high unmet medical needs in central nervous system disorders, sleep-wake conditions, psychiatric illnesses, and inflammatory diseases worldwide; the company, founded in 2003 and headquartered in Washington, DC, markets HETLIOZ (tasimelteon) for non-24-hour sleep-wake disorder and Smith-Magenis syndrome-associated nighttime sleep disturbances, including the LQ oral suspension formulation; Fanapt (iloperidone) for schizophrenia and acute bipolar I disorder, with a long-acting injectable formulation in development; and PONVORY (ponesimod) for multiple sclerosis, pursuing indications in psoriasis and ulcerative colitis with investigational new drug applications accepted by the FDA. Its pipeline encompasses tradipitant (VLY-686), a neurokinin-1 receptor antagonist for gastroparesis, motion sickness, and atopic dermatitis; Bysanti (milsaperidone) for bipolar I disorder, schizophrenia, and major depressive disorder; imsidolimab, licensed from AnaptysBio in February 2025 for generalized pustular psoriasis and potential expansion into other IL-36-related inflammatory conditions; VSJ-110 for dry eye; VPO-227 for secretory diarrhea disorders including cholera; VTR-297 for hematologic malignancies and onychomycosis; VQW-765 for social/performance anxiety; and VGT-1849B, which received FDA orphan drug designation for polycythemia vera, among others. Vanda operates globally with a subsidiary in the United Kingdom and targets rare diseases, neurology, psychiatry, and immunology patient populations through specialized sales forces and marketing campaigns. Recent developments include the $100 million acquisition of PONVORY from Johnson & Johnson, enabling commercial launch in the multiple sclerosis market and new indication pursuits; FDA approval and commercial rollout of Fanapt for acute bipolar I disorder; a global licensing agreement with AnaptysBio for imsidolimab development and commercialization; positive clinical results for tradipitant in preventing GLP-1 induced nausea and vomiting; a collaborative framework with the FDA to resolve disputes; and unsolicited acquisition proposals from Future Pak and Cycle Pharmaceuticals in 2024, which the company reviewed but did not pursue, reflecting ongoing strategic interest amid robust revenue growth to $267.7 million in 2024.
Company News
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript
Arrowstreet Capital Limited Partnership Buys New Position in Vanda Pharmaceuticals Inc. $VNDA
Vanda Pharmaceuticals Q2 Earnings Call Highlights
Vanda Pharmaceuticals Q2 Earnings Call Highlights
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call Transcript